NEW YORK (GenomeWeb News) – Investment firm Jefferies on Tuesday lowered its revenue and price targets for Nanosphere, following the US Food and Drug Administration's denial of a marketing application for its Plavix (clopidogrel) metabolism test.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.